Recombinant Mouse Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (Man1a1)

What is Recombinant Mouse Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (Man1a1)?

Recombinant Mouse Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (Man1a1) is a Golgi-localized enzyme that plays a crucial role in N-glycan maturation by cleaving mannose residues from high-mannose N-glycans. This enzyme is essential for the proper processing of N-linked glycoproteins during their transport through the Golgi apparatus. MAN1A1 specifically cleaves α1,2-linked mannose residues from Man9GlcNAc2 to produce Man5GlcNAc2, which is a critical intermediate in the formation of complex and hybrid N-glycans . The recombinant form is produced through genetic engineering techniques to obtain purified protein for research applications. In mouse models, MAN1A1 has been detected consistently around 72 kDa, with some tissue samples showing an additional band around 60 kDa .

How is MAN1A1 typically detected in experimental settings?

MAN1A1 can be detected through several complementary approaches:

• Western blot analysis: This is commonly used to detect MAN1A1 protein expression, with the enzyme typically appearing at approximately 72 kDa, and sometimes with an additional band around 60 kDa . For quantification, densitometric analysis can be performed against housekeeping proteins like GAPDH.

• qPCR: For measuring MAN1A1 mRNA expression levels in tissues and cell lines . Studies have shown significant correlation between MAN1A1 mRNA and protein levels (Pearson correlation r = 0.586; p = 0.000 for the 72 kDa band) .

• Immunohistochemistry/Immunofluorescence: These techniques are valuable for determining the cellular and subcellular localization of MAN1A1, which is predominantly found in the Golgi apparatus .

• Functional assays: MAN1A1 activity can be assessed through glycan analysis techniques including lectin microarrays, which can measure high-mannose glycan levels as an indirect indicator of MAN1A1 activity .

What are the physiological roles of MAN1A1 in normal tissues?

MAN1A1 plays essential roles in normal physiological functions:

• Protein glycosylation: MAN1A1 ensures proper N-glycan processing, which is crucial for protein folding, stability, and function .

• Cell adhesion regulation: Through modification of adhesion molecule glycosylation, MAN1A1 influences cell-cell and cell-matrix interactions in normal tissues .

• Reproductive biology: In the endometrium, MAN1A1 expression varies throughout the menstrual cycle, with higher expression in the secretory phase compared to the proliferative phase . MAN1A1 is primarily localized in stromal cells of the endometrium .

• Embryo implantation: Recent evidence suggests MAN1A1 plays a critical role in endometrial decidualization, a process essential for successful embryo implantation .

How does MAN1A1 expression influence cancer progression in different tumor types?

Interestingly, MAN1A1 exhibits contrasting prognostic relevance in different cancer types:

Breast Cancer:

• Low/moderate MAN1A1 expression correlates with significantly shorter disease-free intervals (p=0.005) .

• Low MAN1A1 expression correlates significantly with nodal status, higher tumor grade, and increased brain metastasis .

• MAN1A1 appears to function as a tumor suppressor in breast cancer, with reduced expression leading to increased tumor cell adhesion to endothelial cells .

Ovarian Cancer:

• High MAN1A1 expression correlates with significantly shorter recurrence-free survival (p=0.047; Hazard ratio 1.46; 95% CI 1.01–2.11) .

• High MAN1A1 expression correlates significantly with advanced stage, lymph node involvement, and distant metastasis .

• Unlike in breast cancer, MAN1A1 appears to promote cancer progression in ovarian cancer, particularly through enhanced spheroid formation .

This divergent role of MAN1A1 likely stems from the fundamentally different metastatic behaviors of these cancers: breast cancer predominantly spreads hematogenously, while ovarian cancer primarily metastasizes through intraperitoneal dissemination . The different microenvironments and metastatic routes may explain why the same enzyme has opposite effects on prognosis.

What experimental approaches can be used to modulate MAN1A1 activity for functional studies?

Researchers can employ several approaches to modulate MAN1A1 activity:

• Pharmacological inhibition: Alpha-mannosidase inhibitors like kifunensine can effectively inhibit MAN1A1 activity. In experimental settings, kifunensine treatment leads to impaired tumor cell aggregation in ovarian cancer cell lines . The extent of inhibition may vary between cell lines depending on their baseline MAN1A1 expression and the activity of other alpha-mannosidases.

• Genetic knockdown/knockout:

  • siRNA-mediated silencing of MAN1A1 has been effectively used to reduce MAN1A1 expression transiently .

  • CRISPR-Cas9 knockout approaches provide complete elimination of MAN1A1 expression, which has been shown to strongly reduce tumor cell aggregation in spheroid formation assays .

• Overexpression studies: Transfection with MAN1A1-cDNA can be used to rescue MAN1A1 expression in knockdown experiments or to study the effects of MAN1A1 upregulation .

• Rescue experiments: Combining knockdown/knockout with subsequent reintroduction of MAN1A1 can confirm specificity of observed phenotypes .

The choice of approach depends on the specific research question, with each method having distinct advantages for studying acute versus chronic effects of MAN1A1 modulation.

How does MAN1A1 influence the function of cell adhesion molecules?

MAN1A1 significantly impacts the function of cell adhesion molecules through glycosylation:

• Alteration of adhesive properties: Studies have shown that reduced MAN1A1 expression or mannosidase inhibition leads to significantly increased adhesion of breast cancer cells to endothelial cells, suggesting a role in hematogenous metastasis .

• Impact on prognostic relevance: The prognostic significance of certain adhesion molecules depends on MAN1A1 expression. For example:

  • In breast cancer, membrane proteins ALCAM and CD24 were only significantly prognostic in tumors with high MAN1A1 expression .

  • In ovarian cancer, the glycosylated adhesion molecule ALCAM reveals a significant adverse prognostic effect only in the presence of high MAN1A1 expression .

• Spheroid formation: MAN1A1 knockout or inhibition leads to strong reduction of tumor cell aggregation in ovarian cancer spheroid-formation assays . This suggests that:

  • High MAN1A1 activity preserves the functionality or subcellular localization of cell adhesion molecules involved in tumor cell-cell adhesion.

  • Proper N-glycosylation is required for cell adhesion molecules to function effectively in mediating cellular aggregation.

• Protein half-life and localization: Studies with other adhesion molecules like ICAM-1 and JAM-A have demonstrated that N-glycosylation strongly affects protein half-life and subcellular localization , suggesting similar mechanisms may apply to MAN1A1-dependent regulation of adhesion molecules.

What is the relationship between MAN1A1 and high-mannose N-glycans in reproductive biology?

Recent research has revealed an important role for MAN1A1 and high-mannose N-glycans in reproductive biology:

• Endometrial decidualization: Decidualization is the process by which endometrial stromal cells transform to support embryo implantation. Studies have found:

  • MAN1A1 expression increases during normal decidualization .

  • Silencing MAN1A1 increases high-mannose N-glycan levels and inhibits endometrial decidualization .

  • MAN1A1 knockdown significantly decreases the expression of key decidual markers PRL and IGFBP-1 .

• Miscarriage association: Comparative analyses revealed:

  • Miscarriage patients show increased high-mannose glycans and concomitant reduction of MAN1A1 in decidual tissues compared with early pregnant women .

  • The mRNA levels of MAN1A1, MAN1C1, MAN2A1, and MAN2A2 were decreased in decidual tissues from miscarriage patients .

  • This suggests that abnormally elevated high mannosylation resulting from MAN1A1 downregulation may hamper decidualization and potentially contribute to pregnancy loss.

• Regulation mechanisms: MAN1A1 expression in decidual tissues is regulated by complex molecular mechanisms:

  • Long non-coding RNA NEAT1 (lncNEAT1) is increased in the decidual tissues of miscarriage patients .

  • lncNEAT1 interacts with the NPM1-SP1 transcription complex to inhibit MAN1A1 expression .

  • This regulatory pathway represents a potential therapeutic target for preventing decidualization failure.

What are the optimal experimental designs for investigating MAN1A1's role in cancer metastasis?

When designing experiments to investigate MAN1A1's role in cancer metastasis, researchers should consider these methodological approaches:

• In vitro adhesion assays:

  • Cancer cell-endothelial cell adhesion assays to study hematogenous metastasis potential .

  • Cell-matrix adhesion assays using different extracellular matrix components.

  • Compare adhesion properties between MAN1A1-high and MAN1A1-low cell populations.

• Spheroid formation assays:

  • Particularly relevant for ovarian cancer studies where intraperitoneal dissemination is the predominant metastatic route .

  • Culture cancer cells under non-adherent conditions to assess aggregation capacity.

  • Compare spheroid formation between MAN1A1-modulated cells (knockout, knockdown, overexpression).

• Migration and invasion assays:

  • Transwell migration assays to assess motility.

  • Matrigel invasion assays to evaluate invasive potential.

  • Wound healing assays to measure collective cell migration.

• In vivo metastasis models:

  • Orthotopic xenograft models that recapitulate the natural metastatic routes.

  • For breast cancer: intramammary fat pad injection with monitoring of lung/brain metastasis .

  • For ovarian cancer: intraperitoneal injection with monitoring of peritoneal spread and ascites formation .

  • Use of MAN1A1-knockout or MAN1A1-overexpressing cell lines to establish causality.

• Multi-omics approaches:

  • Glycomics to profile N-glycan structures affected by MAN1A1 modulation.

  • Proteomics to identify adhesion molecules and other proteins whose function is altered.

  • Transcriptomics to identify downstream pathways affected by MAN1A1 modulation.

The experimental design should be tailored to the specific cancer type being studied, taking into account the predominant metastatic routes and relevant microenvironmental factors.

How can researchers effectively analyze the impact of MAN1A1 on protein glycosylation?

To effectively analyze the impact of MAN1A1 on protein glycosylation, researchers can employ these methodological approaches:

• Lectin microarrays:

  • Particularly useful for detecting changes in high-mannose N-glycans .

  • Different lectins bind to specific glycan structures, allowing profiling of the glycome.

  • Can be used to compare glycosylation patterns between MAN1A1-high and MAN1A1-low samples.

• Mass spectrometry-based glycomics:

  • Provides detailed structural information about N-glycans.

  • Can identify specific glycan species affected by MAN1A1 modulation.

  • Enables quantitative comparison of glycan profiles between experimental conditions.

• Glycoprotein-specific analyses:

  • Immunoprecipitation followed by glycan analysis to study glycosylation of specific proteins.

  • Western blotting with mobility shift analysis to detect changes in glycosylation status.

  • Enzymatic deglycosylation (PNGase F treatment) to confirm N-glycan-dependent effects.

• Functional glycomics:

  • Integrating glycan structural data with functional assays to establish structure-function relationships.

  • Using glycosylation inhibitors in parallel with MAN1A1 modulation to dissect specific effects.

  • Comparing effects of different mannosidase inhibitors with varying specificities.

• In situ visualization techniques:

  • Fluorescently labeled lectins for microscopy-based detection of specific glycan structures.

  • Proximity ligation assays to detect interactions between glycoproteins of interest.

  • Live-cell imaging to track glycoprotein trafficking and localization.

These approaches should be combined for comprehensive analysis of MAN1A1's impact on protein glycosylation and subsequent cellular functions.

What are the key considerations when designing experiments to reconcile contradictory findings regarding MAN1A1's role in different cancer types?

To reconcile the contradictory findings regarding MAN1A1's role in different cancer types (tumor suppressor in breast cancer vs. oncogenic in ovarian cancer), researchers should consider these key experimental design factors:

• Comparative multi-cancer models:

  • Perform parallel experiments using matched methodologies across different cancer types.

  • Use isogenic cell line panels derived from breast and ovarian cancers to control for genetic background differences.

  • Develop co-culture systems that mimic the tissue-specific microenvironments.

• Pathway context analysis:

  • Investigate MAN1A1 interaction partners and regulatory networks in each cancer type.

  • Perform phosphoproteomics and signalomics to identify divergent downstream pathways.

  • Analyze the expression and activation status of compensatory glycosylation enzymes.

• Metastatic route-specific models:

  • Design experiments that specifically address the different metastatic behaviors:

    • For breast cancer: focus on endothelial cell adhesion and transendothelial migration .

    • For ovarian cancer: focus on spheroid formation, peritoneal adhesion, and anoikis resistance .

• Glycoprotein substrate profiling:

  • Identify cancer type-specific glycoprotein substrates of MAN1A1.

  • Analyze tissue-specific expression of adhesion molecules affected by MAN1A1-mediated glycosylation.

  • Perform comparative glycoproteomics between breast and ovarian cancer samples.

• Patient-derived models:

  • Use patient-derived xenografts and organoids to validate findings in more physiologically relevant systems.

  • Stratify analyses based on molecular subtypes within each cancer type.

  • Correlate MAN1A1 expression with clinical outcomes across large patient cohorts.

• Temporal dynamics:

  • Investigate the role of MAN1A1 at different stages of cancer progression.

  • Compare primary tumors with metastatic lesions for MAN1A1 expression and function.

  • Develop inducible models to study acute versus chronic effects of MAN1A1 modulation.

By systematically addressing these factors, researchers can develop a more nuanced understanding of how the same enzyme can play opposing roles in different cancer contexts.

How can MAN1A1 be targeted for potential therapeutic applications?

Research suggests several promising approaches for targeting MAN1A1 in therapeutic applications:

• Small molecule inhibitors:

  • Kifunensine and other α-mannosidase inhibitors can modulate MAN1A1 activity .

  • Cancer-specific targeting strategies could include:

    • For breast cancer: enhancing MAN1A1 activity to reduce metastatic potential.

    • For ovarian cancer: inhibiting MAN1A1 to reduce spheroid formation and peritoneal spread.

• RNA-based therapeutics:

  • siRNA or antisense oligonucleotides targeting MAN1A1 mRNA to reduce expression.

  • For reproductive applications, targeting the lncNEAT1-NPM1-SP1-MAN1A1 axis could potentially enhance decidualization and improve embryo implantation .

• Glycoengineering approaches:

  • Modifying the glycosylation status of specific adhesion molecules affected by MAN1A1.

  • Developing glycomimetics that can compete with or substitute for natural glycan structures.

• Combination therapies:

  • Combining MAN1A1 modulation with conventional cancer therapies.

  • Targeting multiple enzymes in the N-glycosylation pathway simultaneously.

• Biomarker applications:

  • Using MAN1A1 expression as a prognostic biomarker in breast and ovarian cancers .

  • Developing glycan-based biomarkers that reflect MAN1A1 activity.

These approaches require further validation in preclinical models before advancing to clinical studies.

What are the emerging techniques for studying MAN1A1 function in complex biological systems?

Several cutting-edge techniques are emerging for studying MAN1A1 function in complex biological systems:

• CRISPR-based technologies:

  • CRISPR activation/inhibition (CRISPRa/CRISPRi) for precise modulation of MAN1A1 expression.

  • CRISPR base editing for introducing specific mutations in MAN1A1.

  • CRISPR screens to identify synthetic lethal interactions with MAN1A1.

• Organoid technology:

  • Patient-derived organoids to study MAN1A1 function in near-physiological contexts.

  • Co-culture organoid systems to investigate cell-cell interactions influenced by MAN1A1.

  • Organoid-on-chip platforms for high-throughput screening of MAN1A1 modulators.

• Single-cell multi-omics:

  • Single-cell glycomics to analyze cellular heterogeneity in glycosylation patterns.

  • Integrating single-cell transcriptomics with glycan analysis to correlate MAN1A1 expression with glycan profiles.

  • Spatial transcriptomics to map MAN1A1 expression in complex tissues.

• In vivo glycan imaging:

  • Metabolic glycan labeling for in vivo tracking of MAN1A1-dependent glycosylation.

  • Intravital microscopy to visualize glycan-dependent cell-cell interactions in living organisms.

• Systems biology approaches:

  • Computational modeling of the N-glycosylation pathway to predict the impact of MAN1A1 modulation.

  • Machine learning algorithms to identify patterns in glycomics data associated with MAN1A1 function.

  • Network analysis to map the interactions between MAN1A1 and other glycosylation enzymes.

These emerging techniques will enable more comprehensive understanding of MAN1A1 function in complex biological contexts.